Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Although multitargeted tyrosine kinase inhibitor sunitinib has been used as first‐line therapeutic agent against metastatic renal cell carcinoma (m RCC), the molecular mechanism and functional role per se for its therapeutic performance remains obscure. Our present study revealed that sunitinib‐treated RCC cells exhibit senescence characteristics including increased SA‐β‐gal activity, D c R 2 and D ec1 expression, and senescence‐associated secretary phenotype (SASP) such as proinflammatory cytokines interleukin (IL)‐1α, IL‐6 and IL‐8 secretion. Moreover, sunitinib administration also led to cell growth inhibition, G 1‐S cell cycle arrest and DNA damage response in RCC cells, suggesting therapeutic significance of sunitinib‐induced RCC cellular senescence. Mechanistic investigations indicated that therapy‐induced senescence (TIS) following sunitinib treatment mainly attributed to p53/D ec1 signaling activation mediated by R af‐1/NF‐κ B inhibition in vitro. Importantly, in vivo study showed tumor growth inhibition and prolonged overall survival were associated with increased p53 and D ec1 expression, decreased R af‐1 and K i67 staining, and upregulated SA‐β‐gal activity after sunitinib treatment. Immunohistochemistry analysis of tumor tissues from RCC patients receiving sunitinib neoadjuvant therapy confirmed the similar treating phenotype. Taken together, our findings suggested that sunitinib treatment performance could be attributable to TIS, depending on p53/D ec1 activation via inhibited R af‐1/nuclear factor (NF)‐κ B activity. These data indicated potential insights into therapeutic improvement with reinforcing TIS‐related performance or overcoming SASP‐induced resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046
Senescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909
Therapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824
Pro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
Cellular senescence: putting the paradoxes in perspective
Campisi, J. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.005 · Cited by 368
Zhang, W., Xu, W., & Xiong, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904016 · Cited by 177
Cited by
Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
To clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · BioEssays · doi:10.1002/bies.201670910 · Cited by 108
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
PDCD4 Knockdown Induces Senescence in Hepatoma Cells by Up-Regulating the p21 Expression
Guo, J., Ozaki, I., Xia, J., Kuwashiro, T., Kojima, M., Takahashi, H., Ashida, K., Anzai, K., & Matsuhashi, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00661 · Cited by 29
A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal
Mastri, M., Tracz, A., Lee, C. R., Dolan, M., Attwood, K., Christensen, J. G., Liu, S., & Ebos, J. M. L. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.017 · Cited by 28
Metadata
- Authors
- Zhu, Y., Xu, L., Zhang, J., Hu, X., Liu, Y., Yin, H., Lv, T., Zhang, H., Liu, L., An, H., Liu, H., Xu, J., & Lin, Z.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2013-05-16
- Volume
- 104
- Issue
- 8
- Pages
- 1052-1061
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2020043044
- Cited by
- 71
- References
- 10
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. https://app.cochat.ai/papers/10.1111/cas.12176
- The paper
- Zhu, Y., Xu, L., Zhang, J., Hu, X., Liu, Y., Yin, H., Lv, T., Zhang, H., Liu, L., An, H., Liu, H., Xu, J., & Lin, Z. (2013). Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Science. https://doi.org/10.1111/cas.12176
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.